0001193125-23-052344.txt : 20230228 0001193125-23-052344.hdr.sgml : 20230228 20230228080533 ACCESSION NUMBER: 0001193125-23-052344 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230228 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230228 DATE AS OF CHANGE: 20230228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001783183 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824151574 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39094 FILM NUMBER: 23678516 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (877) 742-8466 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 8-K 1 d413841d8k.htm 8-K 8-K
false 0001783183 0001783183 2023-02-28 2023-02-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 28, 2023

 

 

PHATHOM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39094   82-4151574

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

100 Campus Drive, Suite 102

Florham Park, New Jersey 07932

(Address of principal executive offices) (Zip Code)

(877) 742-8466

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   PHAT   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On February 28, 2023, Phathom Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

 

Item 9.01.

Financial Statements and Exhibits.

    (d) Exhibits

 

Exhibit

    No.    

   

Description

99.1    Press Release issued on February 28, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    PHATHOM PHARMACEUTICALS, INC.
Date: February 28, 2023     By:  

/s/ Larry Miller

      Larry Miller
      General Counsel and Secretary
 EX-99.1 2 d413841dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

 

  •  

Meeting scheduled in March 2023 with the U.S. Food and Drug Administration (FDA) to discuss stability data and resubmission requirements for erosive GERD and H. pylori New Drug Applications

FLORHAM PARK, N.J., February 28, 2023 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

“Over the past year, our teams made significant progress to advance the development and commercial potential of vonoprazan. We obtained FDA approval of our first products, aligned with the FDA on a near final label for erosive GERD, and delivered our third positive Phase 3 trial for vonoprazan in a third potential indication,” said Terrie Curran, President and Chief Executive Officer of Phathom. “While our anticipated commercial launch is on hold pending resolution of the previously announced nitrosamine impurity issue, we are confident in the progress we have made in generating additional stability data, and based on initial testing results, we believe the mitigation measures put in place are achieving their intended effects. We have a meeting scheduled with the FDA in March to discuss our proposed resubmission plan and align on potential review timelines to help make vonoprazan available to patients as soon as possible. We look forward to meeting with the FDA and expect to share more details about our progress once we have obtained additional clarity.”

Full Year 2022 and Recent Business Highlights:

 

  •  

Phathom delivered positive topline results for the primary endpoint from its third Phase 3 trial, PHALCON-NERD-301, evaluating the daily dosing of vonoprazan for the treatment of non-erosive gastroesophageal reflux disease (GERD) in adults. In the four-week placebo-controlled period of the study, both vonoprazan doses (10 mg and 20 mg) met the primary endpoint by showing a statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001). The blinded 20-week long-term extension period of the trial is currently ongoing to further evaluate the safety and efficacy of both doses of vonoprazan after six months of continuous daily use. Full results from the trial are anticipated in the second half of 2023 and are expected to form the basis for Phathom’s regulatory submission for vonoprazan as a daily treatment for patients with non-erosive GERD.

 

  •  

Phathom reported positive topline results from a Phase 2 proof-of-concept trial for vonoprazan dosed as needed (on-demand) for non-erosive GERD, demonstrating statistical significance for all doses of vonoprazan (10 mg, 20 mg, 40 mg) when compared to placebo (p<0.0001). Significant differences in complete and sustained relief occurred as early as one hour after dosing and these differences were maintained over 24 hours. Phathom believes these results support the potential of vonoprazan to provide patients with a rapid relief agent to treat non-erosive GERD on an as needed basis, a dosing regimen for which proton pump inhibitors (PPIs) are not approved in the U.S.

  •  

On May 3, 2022, Phathom announced the FDA approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK™ (vonoprazan, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection in adults. These products contain antibiotics conveniently packaged with vonoprazan, a novel potassium-competitive acid blocker (PCAB) and the first innovative acid suppressant from a new drug class approved in the U.S. in over 30 years.

 

  •  

Phathom secured up to $300 million in non-dilutive capital under the terms of its revenue interest financing agreement. The agreement provided an upfront $100 million cash payment and has the potential to provide an additional $175 million upon FDA approval of vonoprazan for erosive GERD, and $25 million upon achievement of a sales milestone, with total royalty payments capped at 2.0x invested capital.

 

  •  

Upon approval and in advance of the planned commercial launches of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, Phathom secured coverage for 51% of commercial lives to date.

Fourth Quarter and Full Year 2022 Financial Results:

 

  •  

Net loss for the fourth quarter ended December 31, 2022 was $55.0 million, compared to $35.8 million for fourth quarter 2021. Fourth quarter 2022 net loss included a non-cash charge related to stock-based compensation of $6.7 million compared to $4.3 million for fourth quarter 2021. Net loss for the year ended December 31, 2022 was $197.7 million, compared to $143.9 million for the full year ended December 31, 2021. Full year 2022 net loss included a non-cash charge related to stock-based compensation of $24.1 million, compared to $16.8 million in 2021.

 

  •  

Research and development expenses for the fourth quarter 2022 were $15.9 million, an increase of $2.3 million compared to $13.6 million for fourth quarter 2021. The increase was a result of increased clinical trial costs related to the development of vonoprazan, including activity related to the ongoing Phase 3 PHALCON-NERD-301 daily dosing trial. Research and development expenses for the full year 2022 were $71.4 million, a decrease of $0.9 million compared to $72.3 million in 2021. The decrease was a result of decreased regulatory costs partially offset by increased clinical trial costs related to the development of vonoprazan.

 

  •  

General and administrative expenses for the fourth quarter 2022 were $30.7 million, an increase of $11.2 million compared to $19.5 million for fourth quarter 2021. The increase was primarily due to the ongoing buildout of commercial infrastructure in support of the planned U.S. launch of VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori infection, and, if approved, VOQUEZNA for erosive GERD. General and administrative expenses for the full year 2022 were $101.0 million, an increase of $38.3 million compared to $62.7 million in 2021. The increase was primarily due to the ongoing buildout of commercial infrastructure in support of the planned U.S. launch of VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori infection, and, if approved, VOQUEZNA for erosive GERD.

  •  

As of December 31, 2022, cash and cash equivalents were $155.4 million. An additional $100 million is available under Phathom’s term loan with Hercules Capital.

 

  •  

Based on its current operating plan, including the funds currently available under its existing term loan and following approval of vonoprazan for erosive GERD, available under its royalty interest financing agreement, Phathom believes it will have sufficient capital to fund operations through 2024.

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.

Forward Looking Statements

Phathom cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding Phathom’s expectations of generating stability data necessary to support the proposed shelf life of vonoprazan and the potential approval of its erosive esophagitis NDA and post approval supplements for its H. pylori NDAs, and anticipated product launches in H. pylori and erosive esophagitis; the expected timing of topline data from the Phase 3 trial of vonoprazan as a daily treatment for patients with non-erosive GERD; the potential of vonoprazan to provide patients with a rapid relief agent to treat non-erosive GERD; and that Phathom will have sufficient capital to fund operations through 2024. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Phathom’s business, including, without limitation: Phathom may be unable to generate the required data to meet the acceptable intake of its nitrosamine impurity, or may be unable to reduce the impurity to an acceptable level throughout the shelf life of the product, to obtain approval its erosive esophagitis NDA or to bring vonoprazan to market for patients with erosive esophagitis, if approved, or for patients with H. Pylori; risks associated with product manufacturing or formulation changes required to be made in connection with achieving the acceptable daily intake limit of the nitrosamine detected in vonoprazan

drug product; the FDA may disagree that the existing safety and efficacy data, together with additional data, is sufficient to approve the erosive esophagitis NDA or supplements to the H. pylori NDAs; the inherent risks of clinical development of vonoprazan; Phathom’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Phathom’s ability to access additional capital under its term loan facility and royalty interest finance agreements is subject to certain conditions; Phathom’s ability to obtain and maintain intellectual property protection for vonoprazan; Phathom’s ability to comply with its license agreement with Takeda; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

MEDIA CONTACT

Nick Benedetto

1-877-742-8466

media@phathompharma.com

INVESTOR CONTACT

Eric Sciorilli

1-877-742-8466

ir@phathompharma.com

© 2023 Phathom Pharmaceuticals. All rights reserved.

VOQUEZNA, VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks or trademarks of Phathom Pharmaceuticals, Inc.

Selected Condensed Balance Sheets

(in thousands)

 

     December 31,
2022		      December 31,
2021		  

Assets

      

Cash and cash equivalents

    $ 155,385      $ 183,259  

Total assets

    $ 164,810      $ 189,431  

Total liabilities

    $ 239,624      $ 117,275  

Total stockholders’ equity (deficit)

    $ (74,814 )     $ 72,156  

Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

 

     Three Months Ended
December 31,		      Years Ended
December 31,		  
     2022      2021      2022      2021  

Operating expenses:

            

Research and development

    $ 15,946      $ 13,553      $ 71,441      $ 72,338  

General and administrative

      30,695        19,487        100,999        62,742  
  

 

 

     

 

 

     

 

 

     

 

 

  

Total operating expenses

      46,641        33,040        172,440        135,080  
  

 

 

     

 

 

     

 

 

     

 

 

  

Loss from operations

      (46,641 )       (33,040 )       (172,440 )       (135,080 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

Other income (expense):

            

Interest income

      1,286        6        2,132        41  

Interest expense

      (9,603 )       (2,775 )       (27,305 )       (6,788 ) 

Other expense

      (89 )       (17 )       (110 )       (2,056 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

Total other expense

      (8,406 )       (2,786 )       (25,283 )       (8,803 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

Net loss and comprehensive loss

    $ (55,047 )     $ (35,826 )     $ (197,723 )     $ (143,883 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

Net loss per share, basic and diluted

    $ (1.33 )     $ (0.95 )     $ (5.05 )     $ (3.89 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

Weighted-average shares of common stock outstanding, basic and diluted

      41,310,887        37,758,061        39,118,215        37,002,959  
  

 

 

     

 

 

     

 

 

     

 

 

  
 EX-101.SCH 3 phat-20230228.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 phat-20230228_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 phat-20230228_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Feb. 28, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001783183
Document Type 8-K
Document Period End Date Feb. 28, 2023
Entity Registrant Name PHATHOM PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39094
Entity Tax Identification Number 82-4151574
Entity Address, Address Line One 100 Campus Drive
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Florham Park
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07932
City Area Code (877)
Local Phone Number 742-8466
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol PHAT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
XML 7 d413841d8k_htm.xml IDEA: XBRL DOCUMENT 0001783183 2023-02-28 2023-02-28 false 0001783183 8-K 2023-02-28 PHATHOM PHARMACEUTICALS, INC. DE 001-39094 82-4151574 100 Campus Drive Suite 102 Florham Park NJ 07932 (877) 742-8466 false false false false Common Stock, par value $0.0001 per share PHAT NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d413841d8k.htm d413841dex991.htm phat-20230228.xsd phat-20230228_lab.xml phat-20230228_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d413841d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d413841d8k.htm" ] }, "labelLink": { "local": [ "phat-20230228_lab.xml" ] }, "presentationLink": { "local": [ "phat-20230228_pre.xml" ] }, "schema": { "local": [ "phat-20230228.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "phat", "nsuri": "http://www.phathompharma.com/20230228", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d413841d8k.htm", "contextRef": "duration_2023-02-28_to_2023-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d413841d8k.htm", "contextRef": "duration_2023-02-28_to_2023-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.phathompharma.com//20230228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001193125-23-052344-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-052344-xbrl.zip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